These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32218998)

  • 21. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():374. PubMed ID: 26381878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Origins and Risk Factors for Serotype-2 Vaccine-Derived Poliovirus Emergences in Africa During 2016-2019.
    Gray EJ; Cooper LV; Bandyopadhyay AS; Blake IM; Grassly NC
    J Infect Dis; 2023 Jun; 228(1):80-88. PubMed ID: 36630295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Circulating vaccine-derived poliovirus type 2 outbreak in Democratic Republic of Congo 2011-2012].
    Bazira L; Coulibaly T; Mayenga M; Ncharre C; Yogolelo R; Mbule A; Moudzeo H; Lwamba P; Mulumba AW; Cabore J
    Bull Soc Pathol Exot; 2015 Oct; 108(4):235-41. PubMed ID: 26288132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM; Duintjer Tebbens RJ
    BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances in researches of serotype 2 novel oral polio vaccine].
    Chen SY; Li Y; Yang JS; Yin XX
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Mar; 55(3):413-417. PubMed ID: 33730837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
    Duintjer Tebbens RJ; Thompson KM
    BMC Infect Dis; 2015 Sep; 15():390. PubMed ID: 26404780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story.
    Bandyopadhyay AS; Zipursky S
    Lancet Infect Dis; 2023 Feb; 23(2):e67-e71. PubMed ID: 36162417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials.
    Gast C; Bandyopadhyay AS; Sáez-Llorens X; De Leon T; DeAntonio R; Jimeno J; Aguirre G; McDuffie LM; Coffee E; Mathis DL; Oberste MS; Weldon WC; Konopka-Anstadt JL; Modlin J; Bachtiar NS; Fix A; Konz J; Clemens R; Costa Clemens SA; Rüttimann R
    J Infect Dis; 2022 Sep; 226(5):852-861. PubMed ID: 34610135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. World Health Organization Guidelines for Containment of Poliovirus Following Type-Specific Polio Eradication - Worldwide, 2015.
    Previsani N; Tangermann RH; Tallis G; Jafari HS
    MMWR Morb Mortal Wkly Rep; 2015 Aug; 64(33):913-7. PubMed ID: 26313474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.
    Famulare M; Chang S; Iber J; Zhao K; Adeniji JA; Bukbuk D; Baba M; Behrend M; Burns CC; Oberste MS
    J Virol; 2016 Jan; 90(1):317-31. PubMed ID: 26468545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.
    Orenstein WA;
    Pediatrics; 2015 Jan; 135(1):196-202. PubMed ID: 25548328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating stability of attenuated Sabin and two novel type 2 oral poliovirus vaccines in children.
    Wahid R; Mercer L; Gast C; De Leon T; Sáez-Llorens X; Fix A; Macadam A; Stephens L; Chumakov K; Smits SL; Murreddu M; Konopka-Anstadt JL; Steven Oberste M; Burns CC; Andino R; Bachtiar NS; Tritama E; Bandyopadhyay AS; Aguirre G; Rüttimann R; Konz JO
    NPJ Vaccines; 2022 Feb; 7(1):19. PubMed ID: 35149714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019.
    Jorba J; Diop OM; Iber J; Henderson E; Zhao K; Quddus A; Sutter R; Vertefeuille JF; Wenger J; Wassilak SGF; Pallansch MA; Burns CC
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(45):1024-1028. PubMed ID: 31725706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of a genetically stable, novel oral type 2 poliovirus vaccine in the poliomyelitis endgame.
    Costa Clemens SA; Santos GML; Gonzalez I; Clemens R
    Rev Panam Salud Publica; 2023; 47():e99. PubMed ID: 37405121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates.
    Kroiss SJ; Famulare M; Lyons H; McCarthy KA; Mercer LD; Chabot-Couture G
    Vaccine; 2017 Oct; 35(42):5674-5681. PubMed ID: 28890193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.
    Shin WJ; Hara D; Gbormittah F; Chang H; Chang BS; Jung JU
    mBio; 2018 Nov; 9(6):. PubMed ID: 30482835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
    Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notes from the Field: Circulating Vaccine-Derived Poliovirus Outbreaks - Five Countries, 2014-2015.
    Morales M; Nnadi CD; Tangermann RH; Wassilak SG
    MMWR Morb Mortal Wkly Rep; 2016 Feb; 65(5):128-9. PubMed ID: 26866942
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling the dynamics of oral poliovirus vaccine cessation.
    Thompson KM; Duintjer Tebbens RJ
    J Infect Dis; 2014 Nov; 210 Suppl 1():S475-84. PubMed ID: 25316870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.